You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo

    SBC: Achillion Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (MTB) is probably the most ubiquitous microbial pathogen in the world today infecting one-third of the total population and causing millions of active tuberculosis (TB) cases each year. The economic costs are substantial and more than one million people die of TB infections each year. Before the arrival of antimicrobial therapy, TB wa ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Accelerated Discovery and Development of New Pain Therapeutics

    SBC: AESTUS THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neuropathic pain is a common complication of cancer, diabetes mellitus, viral infections, and other causes. Although physicians currently employ a variety of treatments to manage moderate to severe neuropathic pain, including non-steroidal anti-inflammatory drugs, opioids, tricyclic antidepressants, anti- seizure medications, serotonin-norepinephrine reupta ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a method to multiplex ChIP-SEQ and ChIP-chip experiments

    SBC: AFFOMIX, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): The immediate objective of our research is to generate a method that will enable researchers to multiplex Chromatin ImmunoPreciptation-Sequencing (ChIP-Seq) analysis in a single Next generation DNA sequencing run. In the to-be-developed method: i) a set of antibodies directed against specific DNA-binding proteins are uniquely bar-coded with a DNA 'ZipCode;' ii) ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. High-throughput screening and identification of scFv antibodies against glycosyla

    SBC: AFFOMIX, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): The specific goal of this proposal is to develop a high-throughput method to identify scFv antibodies that recognize post-translationally modified proteins. We propose to complete a proof-of-concept for a new type of affinity screening process based on emulsion, secretion, and capture, which we term ESCape . In the proposed phage ESCape method, E. coli transfo ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A bifunctional antibody screening system for both phage display and yeast two-hyb

    SBC: AFFOMIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This is a proposal to establish a proof-of-principle for a vector system to isolate high-affinty antibodies through selective rounds in both yeast and Escherichia coli. Antibodies have quickly become extremely useful as therapeutic medicines to treat a wide-variety of disorders. We propose to develop a means of making the discovery of immunotherapeutics faster ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. A Flow Through Cell Counting Assay

    SBC: ALLIED INNOVATIVE SYSTEMS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long-term goal of the proposed research is to develop a novel quantitative flow through cell counting method for enumeration of CD4+ T lymphocytes in human blood. CD4 cell counts are needed to stage and monitor HIV-infected patients. In adults, the absolute number of CD4+ T cells per microlitre of blood has critical prognostic and therapeutic implications, ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. High throughput screening of bacterial collections for surface proteins of commer

    SBC: APD LIFE SCIENCES, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): There is a recognized need for development of protein capture tools that will reliably detect a variety of targets, over a broad range of concentrations, for use with human plasma and other complex sample mixtures for diagnostic and therapeutic applications. The products from our PEARL [Pathogen-Encoded Adaptable Receptor Library] technology will yield antibody ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Endotracheal Tube Monitor for Neonates

    SBC: ARTANN LABORATORIES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Each year, at least 10,000 critically sick babies in respiratory failure are intubated for ventilator support. For these babies, intubation bears major health risks such as airway emergencies, cardiopulmonary arrest, pneumothoraces. Neonates, however young, can be quite active, leading to undesirable tube movement and unplanned extubations. To date, there exist ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Synthetic nanocapsule malaria vaccines

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to produce novel synthetic malaria vaccines based on epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the causative agent of human malaria. Malaria is one of the major diseases in the developing world, causing 200-500 million new infections and over 1 million deaths each year, primarily in young children in Af ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Point-of Care System for Determination of Bilirubin Capacity in Neonates

    SBC: AVIV BIOMEDICAL INC            Topic: NCRR

    DESCRIPTION (provided by applicant): Human serum albumin is capable of binding bilirubin with high affinity, thus sequestering it and mitigat- ing its harmful neurological effects in jaundiced newborns. Despite considerable work indicating that the level of bilirubin in the blood relative to the level of albumin binding sites is a key factor in assessing risk for bilirubin associated brain damage, ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government